A combination of search terms was applied pertinent to the topic of obesity pharmacotherapy including obesity pharmacotherapy, GLP-1 receptor agonist, semaglutide, tirzepatide, liraglutide, naltrexone/bupropion, phentermine/topiramate, orlistat, retatrutide, survodutide, weight loss medications, Body Mass Index, BMI, weight management, weight loss and obesity
Adverse effects include gastrointestinal symptoms and arrhythmias such as VPBs, VT, APBs, atrial tachycardia, and varying degrees of AV block in patients with structural heart disease or electrolyte disturbances (56)(58)
Evidence for sirtuin-activating diets as a standalone weight-loss intervention remains limited
This is the foundational paper that established the GLP-1R-mediated suppression of human adipose stem cell function and is cited extensively across subsequent reviews including Paschou 2025 and Ridha 2024
35:30 - Mouse Trials or Straight to Humans
Antigen-presenting cells (APCs)